Rallybio Corporation (RLYB)
NASDAQ: RLYB · Real-Time Price · USD
15.72
+0.07 (0.45%)
At close: Nov 13, 2026, 4:00 PM EST
15.78
+0.06 (0.40%)
After-hours: Nov 13, 2026, 7:30 PM EST
Rallybio Revenue
Rallybio had revenue of $434.00K in the twelve months ending September 30, 2026, down -35.61% year-over-year. In the year 2025, Rallybio had annual revenue of $858.00K with 34.91% growth. That makes Rallybio the 44,699th largest company in the world by revenue and 6,376th in the United States.
Revenue (ttm)
$434.00K
Revenue Growth
-35.61%
P/S Ratio
195.01
Revenue / Employee
$72,333
Employees
6
Market Cap
84.64M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 858.00K | 222.00K | 34.91% |
| Dec 31, 2024 | 636.00K | - | - |
| Dec 31, 2023 | - | - | - |
| Dec 31, 2022 | - | - | - |
| Dec 31, 2021 | - | - | - |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. It does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Coherus Oncology | 53.64M |
| Seer, Inc. | 14.08M |
| Rani Therapeutics Holdings | 6.58M |
| Cibus | 4.35M |
| Atara Biotherapeutics | 3.97M |
| Genelux | 8.00K |
RLYB News
- 2 days ago - Correction to Press Release Announcing Reverse Stock Split of Rallybio Common Stock in Connection with the Proposed Merger with Avenzo - Business Wire
- 3 days ago - Rallybio announces one-for-two reverse stock split - TheFly
- 3 days ago - Rallybio Announces Reverse Stock Split of Common Stock in Connection with the Proposed Merger with Avenzo - Business Wire
- 7 days ago - Rallybio Corp trading halted, news pending - TheFly
- 9 days ago - Rallybio Transcript: AGM 2026 - Transcripts
- 17 days ago - Rallybio Quarterly report: Q3 2026 - Filings
- 3 months ago - Rallybio Quarterly report: Q2 2026 - Filings
- 5 months ago - Rallybio to acquire Avenzo Therapeutics through merger transaction - TheFly